ストックスクリーナーアプリを入手
54.25
1.31%
0.70
アフターアワーズ：
54.25
前日終値:
$53.55
開ける：
$54.15
24時間の取引高:
1.31M
Relative Volume:
0.60
時価総額：
$6.91B
収益：
$947.36M
当期純損益:
$392.47M
株価収益率:
17.96
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
-3.25%
1か月 パフォーマンス:
-8.64%
6か月 パフォーマンス:
+12.09%
1年 パフォーマンス:
+5.46%
1日の値動き範囲:
$53.44
$54.76
1週間の範囲:
$52.73
$56.32
52週間の値動き範囲:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
54.25 | 6.91B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus
Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - Insider Monkey
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance
Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance
Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus
Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey
(HALO) Investment Report - news.stocktradersdaily.com
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World
Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal
Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK
Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus
Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail
Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance
New Strong Buy Stocks for May 28th - The Globe and Mail
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus
Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq
Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance
Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus
Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow
Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance
Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus
Halozyme stock holds $78 target despite Medicare concerns - Investing.com
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):